Search results for: Pricing and Reimbursement
Filter search results
Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches
1 August 2011
…which value based pricing might be operationalised, categorise these by developing a taxonomy of approaches, and provide an initial assessment of the challenges, pros and cons of each. They review…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
1 April 2019
…Report fails to promote mechanisms and processes (value assessment and related pricing and purchasing arrangements) that are key to efficient pricing and use of cancer medicines. This is a missed…
The Expanding Value Footprint of Oncology Treatments
13 May 2014
…may not be evident at the time of first approval and value can vary both over time and by indication. This may result in pricing and reimbursement decisions that fail…
Forecasting the Challenges and Economics of Drug Development in 2022
9 July 2013
…diversity of public and private partners. 3. Approval, pricing and financing regimes must change to realize the promise of the new science. Regulatory bodies need both personnel and procedures capable…
OHE at iHEA: HTA in Emerging Markets, Personalised Medicine, EQ-5D mapping
6 August 2013
…Three countries were explored in greater depth: Kenya, South Africa and Vietnam. Although HTA could be crucial to solving the challenges of limited resources and substantial demand in LMICs, awareness…
R&D for new drugs to tackle AMR is a high-return investment for all EU member states
19 July 2024
…co-authored by OHE’s Adrian Towse, and the ARMoR model utilised input from OHE’s Grace Hampson, and is based on work by Adrian Towse and Rachel Silverman-Bonnifield. Anderson et al. propose…
The true cost and burden of frontotemporal dementia: Early insights into a pressing challenge
22 September 2025
…validation of novel biomarkers and the development of AI-driven diagnostic tools. The consortium brings together experts and institutions from Finland, Germany, Italy, Lithuania, Luxembourg, the Netherlands, Spain, and the United…
Around The World in HTAs: The Slovak Republic – Valuing the Future
13 September 2023
…working groups, NIHO, and the Section of Pharmacy and Drug Policy. Expert working groups provide clinical assessments, NIHO provides technology assessments, and The Section of Pharmacy and Drug Policy issues…
Pricing in Emerging Markets: Income, Competition and Procurement
16 August 2011
…is far less in doubt, allowing competition on price, not brand and (2) the procurement process attracts multinational generic suppliers that have scale and other cost and quality advantages relative…